Tucatinib with capecitabine and trastuzumab in advanced HER2-positive metastatic breast cancer with and without brain metastases: a non-randomised, open-label, phase 1b study - Murthy, R; Borges, V F; Conlin, A (Lancet Oncol, 2018)